All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Immune comparison

LL-37 vs Thymogen

An educational, source-based comparison of LL-37 and Thymogen — how each peptide works, what it's researched for, and what to know before going deeper.

Immune · Antimicrobial
LL-37

Human cathelicidin peptide with antimicrobial and immune-modulating activity.

Mechanism

The only human cathelicidin antimicrobial peptide. Research demonstrates broad antimicrobial activity against bacteria, viruses, and fungi, plus immunomodulatory effects on neutrophils, macrophages, and wound healing.

Research areas
  • Chronic biofilm infections
  • Wound healing and dermatology
  • Innate immune modulation
Considerations
  • Not FDA-approved.
  • Pro-inflammatory effects possible at higher doses.
Full LL-37 profile →
Immune · Bioregulator
Thymogen

Dipeptide bioregulator for immune system modulation.

Mechanism

A synthetic dipeptide (Glu-Trp) in the Khavinson bioregulator family. Research suggests modulation of thymic and immune cell gene expression, supporting T-cell maturation and innate immune response in aged models.

Research areas
  • Immunosenescence and age-related immune decline
  • Post-infectious immune recovery
  • Chronic fatigue and immune dysregulation
Considerations
  • Russian bioregulator research; limited independent replication.
  • Not FDA-approved.
Full Thymogen profile →

Trial-evidence rating

Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.

LL-37
Preliminary

Early-stage research; conclusions are tentative.

1 cited study
Thymogen
Preliminary

Early-stage research; conclusions are tentative.

1 cited study

Study-by-study comparison

PeptideStudySourceYearSummary
LL-37LL-37: a multifunctional host-defense peptideFrontiers in Immunology2020Comprehensive review of antimicrobial and immunomodulatory roles.
ThymogenThymogen and immune restoration in elderlyAdvances in Gerontology2016Improved T-cell counts and immune response markers in aged cohorts.

Side-effect & safety grid

LL-37
  • Not FDA-approved.
  • Pro-inflammatory effects possible at higher doses.
Thymogen
  • Russian bioregulator research; limited independent replication.
  • Not FDA-approved.

Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.

LL-37 vs Thymogen — Key differences

  • Class: LL-37 is classified as Immune · Antimicrobial, while Thymogen is Immune · Bioregulator.
  • Primary research focus: LL-37chronic biofilm infections; Thymogenimmunosenescence and age-related immune decline.
  • Tag: Immune · Antimicrobial vs Immune · Bioregulator.

Related comparisons